Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176879 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL59830 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11554769 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL27350 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11584070 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11559655 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL25148109 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| Morpholine SCHEMBL8649532 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL7747664 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL111814 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038056-A | Alkaline cleaning agent for semiconductor corrugated pipe and cleaning and drying method | 沈阳帕卡濑精有限总公司 | 2026-05-15 | — | — | CN | claimed |
| CN-120138748-A | Electrolytic iron foil and application thereof | 宁德翔锐科技有限公司 | 2025-06-13 | — | — | CN | claimed |
| US-20240413396-A1 | ELECTROLYTE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2024-12-12 | — | — | US | claimed |
| EP-4475232-A1 | ELECTROLYTE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAME | Samsung SDI Co., Ltd. (KR) | 2024-12-11 | — | — | EP | claimed |
| CN-119108625-A | Electrolyte for rechargeable lithium battery and rechargeable lithium battery including the same | 三星SDI株式会社 | 2024-12-10 | — | — | CN | claimed |
| US-20240128509-A1 | ELECTROLYTE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2024-04-18 | — | — | US | claimed |
| CN-117417767-B | Crude oil dechlorinating agent and preparation method thereof | 山东科兴化工有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117511529-A | Foaming agent for oil and gas well and preparation method thereof | 滨州市广友石油科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117417767-A | Crude oil dechlorinating agent and preparation method thereof | 山东科兴化工有限责任公司 | 2024-01-19 | — | — | CN | claimed |
| CN-117203815-A | Electrolyte for rechargeable lithium battery and rechargeable lithium battery including the same | 三星SDI株式会社 | 2023-12-08 | — | — | CN | claimed |
| US-20020049195-A1 | Therapeutic ureas | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-04-25 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5998594-A | CHROMOGENIC COMPOUND BEING CHARACTERIZED BY THE PROPERTY OF PRODUCING A REVERSIBLE COLOR CHANGE RESPONSIVE ON BINDING A TARGET SUBSTRATE TO SAID RECEPTOR. | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-12-07 | — | — | US | claimed |
| US-5731305-A | Anti-hypertension compositions of secondary amine-nitric oxide adducts and use thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-03-24 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5208233-A | Cardiovascular disorders | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-05-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049195-A1 | Therapeutic ureas | UTS2R, CHRM3, CHRM2 | MEN1 2553/4885KMT2A 3297/4885GAA 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.